Jeffrey James Swigris, DO, MS

Special Interests

Clinical Interests

My clinical interest is in evaluating and caring for patients with interstitial lung disease (ILD) of any cause. Aryeh Fischer, MD (Division of Rheumatology and Co-Director of the Autoimmune Lung Center) and I co-run a clinical research lab whose goal is to explore interesting and important clinical questions regarding ILD, including ILD related to connective tissue disease. The global focus of my individual research program is on how patients live with and experience ILD, how we assess that experience, and how we, as caretakers, might improve quality of life in patients suffering from ILD. I have a particular interest in developing and investigating so-called patient-reported outcomes (PRO) in ILD. These are instruments designed to capture patients' perceptions of what life is like with ILD and are used to assess whether and how therapeutic interventions affect patients.

Awards & Recognition

2014: Best Doctors in America, Best Doctors, Inc.
2008: Nomination, Clinician of the Year, National Jewish Health
2005: Faculty Teaching Award, Division of Pulmonary and Critical Care Medicine, Stanford Scool of Medicine
2000: Senior Medical Resident of the Year, Cleveland Clinic Foundation
1997: Internal Medicine Fast Track Intern of the Year, Grandview Hospital

Board Certification

Pulmonary Diseases
Critical Care Medicine

Professional Memberships

American College of Chest Physicians
American Thoracic Society

Publications

Swigris JJ, Wamboldt FS, Behr J, du Bois R, King, Jr. TE, Raghu G, Brown KK.  The six-minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.  Thorax 2010;65:173-177 PMID: 19996335

Swigris JJ, Brown KK, Behr J, du Bois R, King, Jr. TE, Raghu G, Wamboldt FS.  The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.  Respir Med 2010;104:296-304 PMID: 19815403

Raghu G, King, Jr. TE, Behr J, Brown KK, du Bois RM, Leconte I, Roux S, Swigris JJ.  Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1).  Eur Respir J 2010;35:118-123 PMID: 19679600 

Yorke J, Jones PW, Swigris JJ.  Development and Validity Testing of an IPF-Specific Verstion of the SGRQ.  Thorax 2010;65:921-926 PMID: 20861296

Swigris JJ, Wilson SR, Green KE, Brown KK, Wamboldt FS.  Development of the ATAQ-IPF: a tool to assess quality of life in IPF.  Health Qual Life Outcomes 2010;8:77 PMID: 20673370

Academic Affiliations

Associate Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver

Teaching & Professional Positions

2011-Present: Associate Professor, National Jewish Health
2011-Present: Associate Professor of Medicine, University of Colorado
2003-2005: Clinical Instructor, Division of Pulmonary and Critical Care Medicine, Stanford University

Website Information

Participation Program for Pulmonary Fibrosis

Conflicts of Interest

National Jewish Health physicians and scientists may collaborate with pharmaceutical or other industries to develop medical and scientific breakthroughs or to provide education on trends in quality medical practice and outcomes to physicians and health professionals around the country. National Jewish Health maintains a strict conflict of interest policy to ensure that all potential conflicts are clearly visible and that management plans are put in place in order to further innovation and education while ensuring the protection of our patients and the integrity of our research. National Jewish Health publicly discloses any payment to our physicians or scientists. View this faculty member’s industry relationships and collaborations.